XNASTRML
Market cap796mUSD
Jan 14, Last price
18.60USD
1D
-4.47%
1Q
-33.09%
IPO
35.10%
Name
Talaris Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-42m
L+113.82%
CFO
-28m
L+334.83%
Dividend
Oct 20, 20231.5118 USD/sh
Earnings
Mar 17, 2025
Profile
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 45,442 | 19,707 | |||
Unusual Expense (Income) | |||||
NOPBT | (45,442) | (19,707) | |||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | (45,442) | (19,707) | |||
Net income | (42,124) 113.82% | (19,701) 2,179,214.16% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 70,468 | 20,000 | |||
BB yield | |||||
| Debt | |||||
Debt current | 442 | 162 | |||
Long-term debt | 609 | 846 | |||
Deferred revenue | |||||
Other long-term liabilities | 57 | 27,125 | |||
Net debt | (201,900) | (7,466) | |||
| Cash flow | |||||
Cash from operating activities | (28,081) | (6,458) | |||
CAPEX | (56) | (5,068) | |||
Cash from investing activities | 3,840 | (5,068) | |||
Cash from financing activities | 156,720 | 19,850 | |||
FCF | (46,682) | (13,156) | |||
| Balance | |||||
Cash | 202,951 | 8,258 | |||
Long term investments | 216 | ||||
Excess cash | 202,951 | 8,474 | |||
Stockholders' equity | (61,982) | (19,900) | |||
Invested Capital | 267,717 | 27,797 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 4,747 | 20,337 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (45,409) | (19,701) | |||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||